Léger Chantal S, Nevill Thomas J
Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, St. Paul's Hospital, and the University of British Columbia, Vancouver, BC.
CMAJ. 2004 May 11;170(10):1569-77. doi: 10.1503/cmaj.1011625.
Hematopoietic stem cell transplantation has been used for many years to treat various malignant and nonmalignant hematologic conditions. However, the high-dose conditioning regimen can lead to major organ dysfunction, life-threatening infection and bleeding. In the allogeneic setting, graft-versus-host disease may also develop, making post-transplant management complex. Once a transplant recipient is discharged from hospital and returns to his or her local community, the primary care physician can play an important role in care. Recipients of stem cell transplants may be severely immunocompromised for many months after transplantation, especially if they are still taking immunosuppressive drugs. Furthermore, endocrine and metabolic deficiencies can develop, and transplant survivors are at risk of a second malignant disease. This review is intended as a basic overview of allogeneic and autologous stem cell transplantation with a special focus on long-term follow-up issues relevant to primary care providers.
造血干细胞移植已被用于治疗各种恶性和非恶性血液疾病多年。然而,高剂量预处理方案可能导致主要器官功能障碍、危及生命的感染和出血。在异基因移植中,还可能发生移植物抗宿主病,使得移植后的管理变得复杂。一旦移植受者出院并回到当地社区,初级保健医生在护理中可发挥重要作用。干细胞移植受者在移植后的许多个月内可能会严重免疫功能低下,尤其是如果他们仍在服用免疫抑制药物。此外,可能会出现内分泌和代谢缺陷,移植幸存者有患第二种恶性疾病的风险。本综述旨在对异基因和自体干细胞移植进行基本概述,特别关注与初级保健提供者相关的长期随访问题。